Slide 1: Strong quarter in a rapidly changing environment
Q1 Strong quarter in a rapidly CellaVision Interim Report changing environment January–March 2025 Organic sales growth: Q1, 2025: 14.1% (21.9) EBITDA margin: Q1, 2025: 34% (29) Jan-Mar Jan-Dec (MSEK) 2025 2024 2024 January 1 – March 31, 2025 Net sales 195 170 723 Gross profit 137 112 487 Net sales i
Slide 2: CEO's Comment
CEO’s Comment The first quarter showed a solid start to the year, with EMEA experienced strong sales across multiple markets, Finally, I want to extend my sincere thanks to our dedicated all regions contributing to growth in a rapidly changing resulting in net sales of SEK 96 m (79) for the quarter,
Slide 3: Sales, Earning and Investments
Sales, Earning and Investments Net Sales and Currency Effects EBITDA and EBITDA Margin Sales per quarter and rolling 12 months Net sales for the first quarter amounted to SEK 195 m (170), an EBITDA for the first quarter increased by 35 percent to increase of 14.6 percent compared to the correspondin
Slide 4: Cash Flow
Cash Flow At the end of the quarter, cash and cash equivalents amounted to SEK 182 m (167). In addition, CellaVision has an unutilized overdraft facility of SEK 30 m (30). Cash flow from operating activities amounted to SEK 61 m (71) in the first quarter of 2025. The solid financial performance and
Slide 5: Development in the Geographical Markets
Development in the Geographical Markets Americas: SEK 78 m (72) EMEA: SEK 96 m (79) APAC: SEK 21 m (19) After two soft quarters, sales in the Americas increased Sales in EMEA increased by 21 percent to SEK 96 m (79), Sales in APAC increased by 12 percent in the first quarter of by 8 percent, reachin
Slide 6: Research and Development
Research and Development Our vision is to elevate healthcare through The development of adapting Fourier the evolution of microscopy. By devoting Ptychographic Microscopy (FPM) in our core considerable resources to research and hematology business continues. Through development, we continue pushing
Slide 7: The Nomination Committee and the Annual General Meeting in 2025
The Nomination Committe and the Annual General Meeting in 2025 The Nomination Committee’s summarized proposal regaring Board before the Annual General Meeting 2025 The Nomination Committee proposes the current Chairman Mikael Worning to be re-elected as Chairman of the Board and proposes re-election
Slide 8: Income Statement in Summary, Group
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group Amounts in ' 000 SEK Note Jan-Mar 2025 Jan-Mar 2024 Jan-Dec 2024 Net sales 4 194,802 170,080 723,217 Cost of goods sold -57,593 -58,014 -236,143 Gross profit 137,209 112,065 487,074 Sales and marketing expenses -33
Slide 9: Per Share Data and Quarterly Earnings Trend
Per Share Data Per share data Jan-Mar 2025 Jan-Mar 2024 Jan-Dec 2024 Earnings per share, before and after dilution, SEK */ 1.74 1.26 5.90 Equity per share, SEK 35.16 31.81 34.20 Number of shares outstanding 23,851,547 23,851,547 23,851,547 Average number of shares outstanding 23,851,547 23,851,547 2
Slide 10: Balance Sheet in Summary, Group
Balance Sheet in Summary, Group Amounts in ' 000 SEK Note 03/31/2025 03/31/2024 12/31/2024 Assets Intangible assets 5 490,783 451,295 487,646 Tangible assets 6 112,307 126,420 119,943 Financial assets 7 2,460 3,942 2,653 Inventory 119,362 122,251 124,823 Trade receivables 7 116,135 81,114 102,824 Ot
Slide 11: Cash Flow Statement in Summary, Group
Cash Flow Statement in Summary, Group Amounts in ' 000 SEK Jan-Mar 2025 Jan-Mar 2024 Jan-Dec 2024 Result before taxes 52,501 38,243 176,860 Adjustment for items not included in cash flow 14,266 16,761 63,144 Income tax paid -8,919 -5,244 -26,154 Cash flow from operating activities before changes in
Slide 12: Income Statement in Summary, Parent Company
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Parent Company Amounts in ' 000 SEK Jan-Mar 2025 Jan-Mar 2024 Jan-Dec 2024 Net sales 148,899 127,620 555,523 Cost of goods sold -31,741 -33,447 -133,896 Gross profit 117,158 94,173 421,627 Sales and marketing expenses -2
Slide 13: Balance Sheet in Summary, Parent Company
Balance Sheet in Summary, Parent Company Amounts in ' 000 SEK 03/31/2025 03/31/2024 12/31/2024 Assets Intangible assets 26,196 29,187 26,944 Tangible assets 7,192 5,385 7,074 Deferred tax assets 755 496 755 Long term receivables from group companies 29,292 35,728 32,162 Financial assets 261,220 262,
Slide 14: Notes
Notes NOTE 1. ACCOUNTING POLICIES NOTE 3. RISKS AND UNCERTAINTIES The Group applies IFRS Accounting Standards, as adopted by the EU. This interim report has been CellaVision is exposed to several risks, which may impact the Group’s development to a greater prepared in accordance with IAS 34 Interim
Slide 15: Notes, Cont'd
Notes, Cont’d NOTE 5. INTANGIBLE ASSETS NOTE 7. FINANCIAL ASSETS AND LIABILITIES Amounts in ' 000 SEK 03/31/2025 03/31/2024 The disclosed value of financial assets, trade receivables, other receivables, cash and bank, trade Capitalised expenditure for development 283,631 223,660 payables, and other
Slide 16: Reconciliation Tables KPIs, Non-IFRS Measures
Reconciliation Tables KPIs, Non-IFRS Measures Equity-asset ratio Amounts in ’ 000 SEK 03/31/2025 03/31/2024 The company presents certain financial measures in the interim report which are not defined according to IFRS. The financial me- Equity 838,533 758,762 trics are used by the company’s manageme
Slide 17: Questions Concerning the Report
Questions Concerning the Report Publication This information constitutes information that CellaVision AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 7:20 a.m. CEST on April 29, 2025. CellaVision is listed on the Nasdaq
Slide 18: This is CellaVision
This is CellaVision Mission To advance laboratory workflow and diagnostic certainty through intelligent microscopy About Us Our Strategic Ambition: The Power of Focus CellaVision is an innovative, global medical technology company Our strategic ambition is to digitalize and improve microscopy Our to